Related Experiment Video

Updated: Oct 22, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.0K

CYP3A deficiency alters bile acid homeostasis and leads to changes in hepatic susceptibility in rats

Xuan Qin1, Yuanjin Zhang2, Jian Lu2

  • 1Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China; Center of Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, United States.

Toxicology and Applied Pharmacology
|August 30, 2021
PubMed

Insights

Cytochrome P450 3A (CYP3A) regulates bile acid (BA) homeostasis. Loss of CYP3A1/2 in rats increased BA levels, altered BA composition, and affected liver function, highlighting CYP3A

Area of Science:

  • Biochemistry
  • Physiology
  • Pharmacology

Background:

  • Cytochrome P450 3A (CYP3A) enzymes are crucial for metabolizing drugs and endogenous compounds.
  • Bile acids (BA) are key regulators of physiological functions through BA receptor activation.

Purpose of the Study:

  • To investigate the regulatory role of CYP3A in maintaining bile acid homeostasis and liver function.
  • To understand how CYP3A gene knockout affects bile acid metabolism and related physiological parameters in rats.

Main Methods:

  • Utilized CYP3A1/2 gene knockout (KO) and wild-type (WT) rat models.
  • Analyzed bile acid concentrations in serum, liver, and small intestine.
  • Assessed serum total cholesterol levels and the transcription of BA receptors (PXR, TGR5).

Main Results:

  • CYP3A1/2 KO rats exhibited significantly increased BA concentrations in serum, liver, and small intestine compared to WT rats.
  • BA pool alterations in KO rats were attributed to decreased catabolism and increased synthesis, affecting BA hydrophobicity and aging-dependent changes.
  • Serum total cholesterol decreased in KO rats, alongside altered BA receptor transcription and impacts on liver function and morphology.

Conclusions:

  • CYP3A is identified as a critical regulator of bile acid homeostasis in rats.
  • CYP3A influences BA pool size, composition, and the balance of synthesis and catabolism.
  • CYP3A plays a protective role against hepatotoxicity associated with bile acid overload.
Keywords:
Bile acidsCholesterolCytochrome P450 3AGene knockout ratsHomeostasis regulator

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.5K
Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport08:42

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

11.4K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
37
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
34
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
36
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
27